Recent advances in antiretroviral treatment and prevention in HIV-infected patients

Detalhes bibliográficos
Autor(a) principal: Maltez, F
Data de Publicação: 2011
Outros Autores: Doroana, M, Branco, T, Valente, C
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.10/555
Resumo: PURPOSE OF REVIEW: To discuss new antiretroviral agents (ARVs) and alternative ARV treatment strategies that are currently being evaluated, and to provide an overview of the most recent advances in HIV vaccine development. RECENT FINDINGS: There is a continuous need for improvements in ARV therapy (ART) and several new ARVs are currently undergoing clinical investigation, including the non-nucleoside reverse transcriptase inhibitor rilpivirine, the integrase inhibitor elvitegravir, the chemokine receptor 5 co-receptor antagonist vicriviroc and the maturation inhibitor bevirimat. Strategies to optimize ART, such as treatment interruption, induction-maintenance and class-sparing regimens, are also being evaluated and have had varying success to date. However, vaccination still remains the optimal solution, and one second-generation preventative HIV vaccine has produced encouraging results in a recent phase III trial. SUMMARY: Global prevention and treatment with ARVs that are effective, well tolerated and have high barriers to the development of HIV resistance are the main strategies to fight HIV/AIDS while we await the development of an effective vaccine.
id RCAP_d12bf9fec06e040fb15b08a62ed61a72
oai_identifier_str oai:repositorio.hff.min-saude.pt:10400.10/555
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Recent advances in antiretroviral treatment and prevention in HIV-infected patientsInfecção por HIVHIV infectionsAntiretroviraisAntiretroviral therapyPURPOSE OF REVIEW: To discuss new antiretroviral agents (ARVs) and alternative ARV treatment strategies that are currently being evaluated, and to provide an overview of the most recent advances in HIV vaccine development. RECENT FINDINGS: There is a continuous need for improvements in ARV therapy (ART) and several new ARVs are currently undergoing clinical investigation, including the non-nucleoside reverse transcriptase inhibitor rilpivirine, the integrase inhibitor elvitegravir, the chemokine receptor 5 co-receptor antagonist vicriviroc and the maturation inhibitor bevirimat. Strategies to optimize ART, such as treatment interruption, induction-maintenance and class-sparing regimens, are also being evaluated and have had varying success to date. However, vaccination still remains the optimal solution, and one second-generation preventative HIV vaccine has produced encouraging results in a recent phase III trial. SUMMARY: Global prevention and treatment with ARVs that are effective, well tolerated and have high barriers to the development of HIV resistance are the main strategies to fight HIV/AIDS while we await the development of an effective vaccine.Lippincott Williams & WilkinsRepositório do Hospital Prof. Doutor Fernando FonsecaMaltez, FDoroana, MBranco, TValente, C2012-04-18T14:47:45Z2011-01-01T00:00:00Z2011-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.10/555engCurr Opin HIV AIDS. 2011 Dec;6 Suppl 1:S21-30.1746-630Xinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-09-20T15:51:27Zoai:repositorio.hff.min-saude.pt:10400.10/555Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:51:48.923231Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Recent advances in antiretroviral treatment and prevention in HIV-infected patients
title Recent advances in antiretroviral treatment and prevention in HIV-infected patients
spellingShingle Recent advances in antiretroviral treatment and prevention in HIV-infected patients
Maltez, F
Infecção por HIV
HIV infections
Antiretrovirais
Antiretroviral therapy
title_short Recent advances in antiretroviral treatment and prevention in HIV-infected patients
title_full Recent advances in antiretroviral treatment and prevention in HIV-infected patients
title_fullStr Recent advances in antiretroviral treatment and prevention in HIV-infected patients
title_full_unstemmed Recent advances in antiretroviral treatment and prevention in HIV-infected patients
title_sort Recent advances in antiretroviral treatment and prevention in HIV-infected patients
author Maltez, F
author_facet Maltez, F
Doroana, M
Branco, T
Valente, C
author_role author
author2 Doroana, M
Branco, T
Valente, C
author2_role author
author
author
dc.contributor.none.fl_str_mv Repositório do Hospital Prof. Doutor Fernando Fonseca
dc.contributor.author.fl_str_mv Maltez, F
Doroana, M
Branco, T
Valente, C
dc.subject.por.fl_str_mv Infecção por HIV
HIV infections
Antiretrovirais
Antiretroviral therapy
topic Infecção por HIV
HIV infections
Antiretrovirais
Antiretroviral therapy
description PURPOSE OF REVIEW: To discuss new antiretroviral agents (ARVs) and alternative ARV treatment strategies that are currently being evaluated, and to provide an overview of the most recent advances in HIV vaccine development. RECENT FINDINGS: There is a continuous need for improvements in ARV therapy (ART) and several new ARVs are currently undergoing clinical investigation, including the non-nucleoside reverse transcriptase inhibitor rilpivirine, the integrase inhibitor elvitegravir, the chemokine receptor 5 co-receptor antagonist vicriviroc and the maturation inhibitor bevirimat. Strategies to optimize ART, such as treatment interruption, induction-maintenance and class-sparing regimens, are also being evaluated and have had varying success to date. However, vaccination still remains the optimal solution, and one second-generation preventative HIV vaccine has produced encouraging results in a recent phase III trial. SUMMARY: Global prevention and treatment with ARVs that are effective, well tolerated and have high barriers to the development of HIV resistance are the main strategies to fight HIV/AIDS while we await the development of an effective vaccine.
publishDate 2011
dc.date.none.fl_str_mv 2011-01-01T00:00:00Z
2011-01-01T00:00:00Z
2012-04-18T14:47:45Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.10/555
url http://hdl.handle.net/10400.10/555
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Curr Opin HIV AIDS. 2011 Dec;6 Suppl 1:S21-30.
1746-630X
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Lippincott Williams & Wilkins
publisher.none.fl_str_mv Lippincott Williams & Wilkins
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130382083293184